Opioid Abuse Clinical Presentation
- Author: Adrian Preda, MD; Chief Editor: Eduardo Dunayevich, MD more...
The Diagnostic and Statistical Manual for Mental Disorders, Fifth Edition (DSM-5) defines opioid use disorder as a problematic pattern of opioid use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period:
Taking larger amounts of opioids or taking opioids over a longer period than was intended
Experiencing a persistent desire for the opioid or engaging in unsuccessful efforts to cut down or control opioid use.
Spending a great deal of time in activities necessary to obtain, use, or recover from the effects of the opioid.
Craving, or a strong desire or urge to use opioids.
Using opioids in a fashion that results in a failure to fulfill major role obligations at work, school, or home.
Continuing to use opioids despite experiencing persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of opioids.
Giving up or reducing important social, occupational, or recreational activities because of opioid use.
Continuing to use opioids in situations in which it is physically hazardous.
Continuing to use opioids despite knowledge of having persistent or recurrent physical or psychological problems that are likely to have been caused or exacerbated by the substance.
Tolerance, as defined by either a need for markedly increased amounts of opioids to achieve intoxications or desired effect, or a markedly diminished effect with continued use of the same amount of an opioid.
Withdrawal, as manifested by either the characteristic opioid withdrawal syndrome, or taking opioids to relieve or avoid withdrawal symptoms.
Tolerance and withdrawal criteria are not considered to be met for individuals taking opioids solely under appropriate medical supervision.
Opioid use disorder can be classified by severity as mild, moderate, or severe.
Tolerance is the need for increasing doses of medication to achieve the initial effect of the drug. Tolerance to the analgesic and euphoriant effects and unwanted adverse effects, such as respiratory depression, sedation, and nausea, may develop. However, little tolerance develops to constipation and meiosis. Opioid tolerance usually does not develop in patients with cancer who are being treated for pain; the need for increasing doses in those patients typically is due to an increasing level of pain. No consistent relationship between intrinsic efficacy and tolerance exists.
Continuous administration of opioids leads to physical dependence, the emergence of withdrawal symptoms during abstinence. Physical dependence is expected after 2-10 days of continuous use when the drug is stopped abruptly. The onset and duration of withdrawal varies with the drug used. For example, meperidine withdrawal symptoms peak in 8-12 hours and last for 4-5 days. Heroin withdrawal symptoms usually peak within 36-72 hours and may last for 7-14 days. Symptoms of opioid withdrawal include the following:
Autonomic symptoms - Diarrhea, rhinorrhea, diaphoresis, lacrimation, shivering, nausea, emesis, piloerection (the phrase stopping "cold turkey" refers to piloerection, or "gooseflesh")
Central nervous system arousal - Sleeplessness, restlessness, tremors
Pain - Abdominal cramping, bone pains, and diffuse muscle aching
Craving - For the medication
The phenomenon of addiction is seen in a variable number of patients using drugs. Addiction is characterized as a psychological and behavioral syndrome in which the following features are observed:
Strong tendency to relapse after withdrawal
Addiction must be defined by the observation of maladaptive behaviors, such as adverse consequences due to drug use, loss of control over drug use, and preoccupation with obtaining opioids, rather than pharmacological phenomenon of physiologic dependence, tolerance, and dose escalation. Do not use the term addiction to describe patients who are merely physically dependent. Also, keep in mind that undertreatment in patients with pain may result in a pseudoaddiction, and opioid-seeking behavior may be mistaken for addiction.
Long-acting medications, such as methadone and sustained-release morphine, tend to have slower onset of action, and the rush or high experienced with more rapid-onset medications is not as prominent. Thus, the longer-acting opioids are less likely to be abused.
Mental status effects include depression with any or all of its symptoms, such as sleep disturbances, lack of interest, selflessness, suicidal ideation, and poor coping skills.
Physiological effects: Because tolerance to many of the actions of the opioids develops, it is not likely for even a careful observer to notice the effects of opioids. Small-sized pupils may be the only observation because only very mild tolerance develops for miosis. Inflamed nasal mucosa may be seen if heroin is snorted.
Mental status effects include purposive behaviors, such as complaints and manipulations directed at getting more drug, and anxiety.
Physiologic effects include autonomic signs (eg, tachycardia, high blood pressure, fever, piloerection [goose flesh], mydriasis, and lacrimation, CNS arousal (irritability), and yawning.
In milder abstinence syndrome, clinical features may be limited to dysphoria, craving, yawning, lacrimation, rhinorrhea, and restlessness. In moderate-to-severe cases, piloerection, mydriasis, increased BP and pulse, and GI symptoms are seen as well.
Mental status effects include euphoria, sedation, decreased anxiety, a sense of tranquility, and indifference to pain produced by mild-to-moderate intoxication. Severe intoxication can lead to delirium and coma.
Physiological effects include the following:
Respiratory depression (may occur while the patient maintains consciousness)
Alterations in temperature regulations
Hypovolemia (true as well as relative), leading to hypotension
Needle marks or soft tissue infection
Increase sphincter tone (can lead to urinary retention)
The physical examination provides little information to add in the diagnosis of addiction. However, symptoms of opioid withdrawal and track marks are suggestive of addiction.
Constipation is a common occurrence due to almost continuous use of narcotics.
Opioid dependence is considered a biopsychosocial disorder. Pharmacological, social, genetic, and psychodynamic factors interact to influence abuse behaviors associated with drugs. However, pharmacological factors can be especially prominent, more so than in other types of drug use disorders.
Opioids are strongly reinforcing agents because of the euphoric effects and reported ability to reduce anxiety, increase self esteem, and help coping with daily problems. Most opioids associated with abuse and dependence are mu-agonists, such as heroin, morphine, hydrocodone, oxycodone, and meperidine. Some partial mu-agonists, such as buprenorphine, or some that have no mu-agonism, such as pentazocine, also can possess reinforcing properties. Rapid development of physical dependence and a protracted abstinence syndrome are unique to opioid use and can make abstinence difficult.
Of note, more than half of persons taking 90 days of opioid therapy over a 6-month period remain on opioids years later. Opioid continuation was strongly associated with prior opioid exposure, daily opioid doses of 120 mg or more of morphine equivalent per day, and possible misuse; however the data from which these associations did not include clinical measures of pain or disease severity.
Easy drug availability and acceptable social attitudes make experimentation easy. A high rate of drug use is seen in areas of the city with poor parental functioning and higher crime and unemployment rates. Except for the association between higher exposure to the drug and higher rates of addiction, the precise role of social factors in creating dependent and addictive behaviors is uncertain. Of US service personnel in Vietnam between 1970 and 1972, 42% tried heroin; one half of those personnel became physically dependent, but very few continued to use heroin in their civilian life.
Ego defects in certain patients are postulated to form the basis of drug use. Opioids are theorized to help the ego in managing painful effects such as anxiety, guilt, and anger. Behavioral theory postulates that basic reward-punishment mechanisms perpetuate addictive behavior.
Preexisting mental health diagnoses appear to increase the risk for long-term use of opiods among adolescents and young adults with chronic pain.
Genetic epidemiologic studies suggest a high degree of heritable vulnerability for opioid dependence. Gene polymorphisms for dopamine receptors/transporters, opioid receptors, serotonin receptors/transporters, proenkephalin, and catechol-O-methyltransferase (COMT) all appear to be associated with vulnerability to opioid dependence. Future interventions for opioid dependence may include medications identified through genetic research.
Substance Abuse and Mental Health Services Administration, Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. (SMA) 12-4713. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2012.
CDC. Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014. CDC. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm64e1218a1.htm. December 18, 2015; Accessed: December 24, 2015.
Trust for America's Health and the Robert Wood Johnson Foundation. The Facts Hurt: A State-By-State Injury Prevention Policy Report. The Facts Hurt: A State-By-State Injury Prevention Policy Report. June 2015. Available at http://www.healthyamericans.org/reports/injuryprevention15/.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013. 541-46.
[Guideline] American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders, 2nd edition. In American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006. Arlington, VA: American Psychiatric Association, 2006 (pp. 291–563). Available at http://psychiatryonline.org/content.aspx?bookid=28§ionid=1675010.
Brooks M. FDA clears hydrocodone with abuse-deterrent properties. Medscape Medical News. November 20, 2014. [Full Text].
Lowes R. FDA Restricts Long-term Opioid Use to Combat Abuse. Medscape Medical News. Available at http://www.medscape.com/viewarticle/810732.. Accessed: September 18, 2013.
CDC. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1er.htm. March 15, 2016; Accessed: March 16, 2016.
Brooks M. Grim stats for opioid-related deaths, prescribing in US. Medscape Medical News. July 2, 2014. [Full Text].
Opioid painkiller prescribing: where you live makes a difference. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/vitalsigns/opioid-prescribing. Accessed: July 6, 2014.
Paulozzi LJ, Mack KA, Hockenberry JM. Vital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines - United States, 2012. MMWR Morb Mortal Wkly Rep. 2014 Jul 4. 63(26):563-8. [Medline].
Substance Abuse and Mental Health Services Administration. Results from the 2014 National Survey on Drug Use and Health: Detailed Tables. September 10, 2015. [Full Text].
Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011 Apr 6. 305(13):1315-21. [Medline].
[Guideline] Brooks M. New APS Guideline on Safe Use of Methadone. Medscape Medical News. May 22 2014. [Full Text].
[Guideline] Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014 Apr. 15(4):321-37. [Medline].
Reimer J, Verthein U, Karow A, et al. Physical and mental health in severe opioid-dependent patients within a randomized controlled maintenance treatment trial. Addiction. 2011 Sep. 106(9):1647-55. [Medline].
Grella CE, Lovinger K. 30-Year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California. Drug Alcohol Depend. 2011 Nov 1. 118(2-3):251-8. [Medline]. [Full Text].
Martin BC, Fan MY, Edlund MJ, et al. Long-term chronic opioid therapy discontinuation rates from the TROUP study. J Gen Intern Med. 2011 Dec. 26(12):1450-7. [Medline].
Richardson LP, Russo JE, Katon W, McCarty CA, Devries A, Edlund MJ, et al. Mental Health Disorders and Long-term Opioid Use Among Adolescents and Young Adults With Chronic Pain. J Adolesc Health. 2012 Jun. 50(6):553-8. [Medline]. [Full Text].
Saxon AJ, Oreskovich MR, Brkanac Z. Genetic determinants of addiction to opioids and cocaine. Harv Rev Psychiatry. 2005 Jul-Aug. 13(4):218-32. [Medline].
Narcan Nasal Spray (naloxone intranasal) [package insert]. Radnor, PA: Adapt Pharma, Inc. November, 2015. Available at [Full Text].
FDA News Release. FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose. U.S. Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473505.htm. 2015 Nov 18; Accessed: November 18, 2015.
Cassels C. FDA Okays Handheld Autoinjector for Opioid Overdose. Medscape Medical News. Available at http://www.medscape.com/viewarticle/823039. Accessed: April 9, 2014.
FDA Okays Handheld Autoinjector for Opioid Overdose. Medscape. Available at http://www.medscape.com/viewarticle/823039. Accessed: April 3, 2014.
Community-based opioid overdose prevention programs providing naloxone - United States, 2010. MMWR Morb Mortal Wkly Rep. 2012 Feb 17. 61:101-5. [Medline].
Amato L, Davoli M, A Perucci C, et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005 Jun. 28(4):321-9. [Medline].
Simoens S, Matheson C, Bond C, et al. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract. 2005 Feb. 55(511):139-46. [Medline].
Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005 Aug. 100(8):1090-100. [Medline].
Sigmon SC, Dunn KE, Saulsgiver K, Patrick ME, Badger GJ, Heil SH, et al. A Randomized, Double-blind Evaluation of Buprenorphine Taper Duration in Primary Prescription Opioid Abusers. JAMA Psychiatry. 2013 Oct 23. [Medline].
Cassels C. Longer Taper May Boost Abstinence Rates in Opioid Abusers. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/813231. Accessed: November 4, 2013.
Fiellin DA, Schottenfeld RS, Cutter CJ, et al. Primary Care-Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence: A Randomized Clinical Trial. JAMA Intern Med. 2014 Oct 20. [Medline].
Cassels C. FDA Approves New Treatment for Opioid Dependence. Available at http://www.medscape.com/viewarticle/807379. Accessed: July 19, 2013.
Cassels C. FDA approves Bunavail for opioid addiction. Medscape Medical News. June 10, 2014. [Full Text].
McCance-Katz EF. Office-based buprenorphine treatment for opioid-dependent patients. Harv Rev Psychiatry. 2004 Nov-Dec. 12(6):321-38. [Medline].
FDA. FDA approves first buprenorphine implant for treatment of opioid dependence. U.S. Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503719.htm. May 26, 2016; Accessed: June 7, 2016.
Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA. 2010 Oct 13. 304(14):1576-83. [Medline].
Gowing L, Farrell M, Bornemann R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2004. [Medline].
Tsui JI, Herman DS, Kettavong M, Anderson BJ, Stein MD. Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms. Pain. 2011 Nov. 152(11):2640-4. [Medline]. [Full Text].
Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006 Feb. 63(2):210-8. [Medline].
Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011 Apr 30. 377(9776):1506-13. [Medline].
Tiihonen J, Krupitsky E, Verbitskaya E, et al. Naltrexone Implant for the Treatment of Polydrug Dependence: A Randomized Controlled Trial. Am J Psychiatry. 2012 Feb 17 [Epub ahead of print].
Melville N. COMT Inhibitors Up Adherence to Opioid Maintenance Treatment. Medscape Medical News. Available at http://www.medscape.com/viewarticle/817481. Accessed: December 16, 2013.
Zhang XL, Shi J, Zhao LY, Sun LL, Wang J, Wang GB. Effects of stress on decision-making deficits in formerly heroin-dependent patients after different durations of abstinence. Am J Psychiatry. 2011 Jun. 168(6):610-6. [Medline].
Passetti F, Clark L, Davis P, et al. Risky decision-making predicts short-term outcome of community but not residential treatment for opiate addiction. Implications for case management. Drug Alcohol Depend. 2011 Oct 1. 118(1):12-8. [Medline].
Kleber HD, Gold MS, Riordan CE. The use of clonidine in detoxification from opiates. Bull Narc. 1980. 32(2):1-10. [Medline].
Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2004. [Medline].
Gowing L, Farrell M, Ali R. Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2004. [Medline].
Kunoe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, et al. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2009 Jun. 194(6):541-6. [Medline].
Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009 Oct. 66(10):1108-15. [Medline].
Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005 Oct. 62(10):1157-64. [Medline].
Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011 Sep 7. 9:CD005031. [Medline].
Morasco BJ, Gritzner S, Lewis L, et al. Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder. Pain. 2010 Dec 22. [Medline].
Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006 Jan 17. 144(2):127-34. [Medline].
Centers for Disease Control and Prevention (CDC). Vital Signs: Risk for overdose from methadone used for pain relief – United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2012 Jul. 3;61:[Full Text].
Cassels C. Illicit Use of Pain Meds a Gateway to Heroin Abuse. Medscape Medical News. Available at http://www.medscape.com/viewarticle/809812.. Accessed: August 27, 2013.
Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005 Oct. 6(10):662-72. [Medline].
Davenport L. Avoid Buprenorphine Detox for Prescription Opioid Addiction. Medscape Medical News. Oct 23 2014. [Full Text].
Fischer B, Rehm J, Kim G, Kirst M. Eyes wide shut?--A conceptual and empirical critique of methadone maintenance treatment. Eur Addict Res. 2005. 11(1):1-9; discussion 10-4. [Medline].
Muhuri PK, Gfroerer JC, Davies MC. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States. The Substance Abuse and Mental Health Services Administration (SAMHSA). Available at http://www.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.pdf.. Accessed: August 27, 2013.